The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies